Tenofovir alafenamide-related renal adverse events

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2022年 / 1889卷 / 1期
关键词：
D O I：
10.1007/s40278-022-08683-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4 / 4
相关论文
共 50 条
  • [31] Common adverse drug reactions of elvitegravir, cobicistat, and emtricitabine co-formulated with tenofovir alafenamide or tenofovir disoproxil fumarate
    Segal-Maurer, S.
    Henry, K.
    Benson, P.
    Brinson, C.
    Crofoot, G.
    Guo, S.
    Esser, P.
    Nguyen-Cleary, T.
    Das, M.
    McCallister, S.
    ANTIVIRAL THERAPY, 2016, 21 : A51 - A51
  • [32] Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir
    Brooks, Kristina M.
    Castillo-Mancilla, Jose R.
    Morrow, Mary
    MaWhinney, Samantha
    Blum, Joshua
    Wyles, David L.
    Rowan, Sarah E.
    Ibrahim, Mustafa E.
    Zheng, Jia-Hua
    Johnson, Bethany
    Gomez, Joe
    Choi, Ye Ji
    Cendali, Francesca
    Haas, Hannah
    Roon, Laura
    Bushman, Lane R.
    Anderson, Peter L.
    Kiser, Jennifer J.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (11) : 3303 - 3310
  • [33] A balance of risks: an audit of lipid and renal outcomes in patients prescribed tenofovir alafenamide
    Wu, M-S
    Brawley, D.
    HIV MEDICINE, 2019, 20 : 34 - 35
  • [34] Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials
    Gupta, Samir K.
    Post, Frank A.
    Arribas, Jose R.
    Eron, Joseph J., Jr.
    Wohl, David A.
    Clarke, Amanda E.
    Sax, Paul E.
    Stellbrink, Hans-Juergen
    Esser, Stefan
    Pozniak, Anton L.
    Podzamczer, Daniel
    Waters, Laura
    Orkin, Chloe
    Rockstroh, Juergen K.
    Mudrikova, Tatiana
    Negredo, Eugenia
    Elion, Richard A.
    Guo, Susan
    Zhong, Lijie
    Carter, Christoph
    Martin, Hal
    Brainard, Diana
    SenGupta, Devi
    Das, Moupali
    AIDS, 2019, 33 (09) : 1455 - 1465
  • [35] SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALAFENAMIDE: ASSESSING THE CHANGE IN RENAL FUNCTION IN HEPATITIS B PATIENTS
    Lee, Minna
    Lee, Susan M. K.
    Bernstein, David Eric
    HEPATOLOGY, 2019, 70 : 316A - 316A
  • [36] Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
    Sax, Paul E.
    DeJesus, Edwin
    Crofoot, Gordon
    Ward, Douglas
    Benson, Paul
    Dretler, Robin
    Mills, Anthony
    Brinson, Cynthia
    Wei, Xuelian
    Collins, Sean E.
    Cheng, Andrew
    AIDS, 2018, 32 (12) : 1723 - 1725
  • [37] Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First-Time HBV-Related Decompensated Cirrhosis
    Rong, Xinxin
    Yang, Guangde
    Xu, Yuanyuan
    Chen, He
    Wang, Xia
    Fu, Juanjuan
    Li, Li
    Pan, Xiucheng
    JOURNAL OF VIRAL HEPATITIS, 2025, 32 (04)
  • [38] Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
    De Clercq, Erik
    BIOCHEMICAL PHARMACOLOGY, 2016, 119 : 1 - 7
  • [39] Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?
    Aloy, Blandine
    Tazi, Imane
    Bagnis, Corinne Isnard
    Gauthier, Marion
    Janus, Nicolas
    Launay-Vacher, Vincent
    Deray, Gilbert
    Tourret, Jerome
    AIDS REVIEWS, 2016, 18 (04) : 184 - 192
  • [40] Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
    李玮
    宋宏锐
    中国药物化学杂志, 2018, 28 (05) : 436 - 436
12345